Genetic Technologies Current Ratio 2010-2022 | GENE

Genetic Technologies current ratio from 2010 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Genetic Technologies Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-06-30 $0.01B $0.00B 3.86
2021-12-31 $0.01B $0.00B 6.08
2021-06-30 $0.02B $0.00B 15.82
2020-12-31 $0.01B $0.00B 14.57
2020-06-30 $0.01B $0.00B 10.88
2019-12-31 $0.00B $0.00B 2.95
2019-06-30 $0.00B $0.00B 2.14
2018-12-31 $0.00B $0.00B 3.99
2018-06-30 $0.01B $0.00B 4.13
2017-12-31 $0.01B $0.00B 7.02
2017-06-30 $0.01B $0.00B 7.94
2016-12-31 $0.01B $0.00B 9.47
2016-06-30 $0.01B $0.00B 9.10
2015-12-31 $0.01B $0.00B 13.78
2015-06-30 $0.02B $0.00B 11.28
2014-12-31 $0.00B $0.00B 1.53
2014-06-30 $0.00B $0.00B 1.89
2013-12-31 $0.01B $0.00B 5.50
2013-06-30 $0.00B $0.00B 1.08
2012-12-31 $0.01B $0.00B 3.82
2012-06-30 $0.01B $0.00B 5.16
2011-12-31 $0.01B $0.00B 9.22
2011-06-30 $0.01B $0.00B 3.09
2010-12-31 $0.01B $0.00B 4.34
2010-06-30 $0.00B $0.00B 1.82
2009-12-31 $0.01B $0.00B 2.46
2009-06-30 $0.01B $0.00B 2.67
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.017B $0.005B
Genetic Technologies was the first company in the world to recognize important new applications for `non-coding` DNA (DeoxyriboNucleic Acid). The Company has since been granted patents securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $169.944B 10.37
GSK (GSK) United Kingdom $75.002B 9.40
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.102B 18.95
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.599B 0.00
Arcus Biosciences (RCUS) United States $2.277B 34.17
Biohaven (BHVN) United States $1.119B 0.00
Emergent Biosolutions (EBS) United States $0.618B 4.85
Zymeworks (ZYME) Canada $0.466B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.220B 0.00
Enzo Biochem (ENZ) United States $0.090B 0.00
SQZ Biotechnologies (SQZ) United States $0.036B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00
Ambrx Biopharma (AMAM) United States $0.018B 0.00